FDA Orphan Drug Reviewers Should Seek Help From NIH, Genzyme Says
Executive Summary
CEO Meeker suggests a program where NIH scientists have a rotation at FDA where they take part in drug reviews for an extended period, instead of only for a short time as a consultant.